Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignEarly changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcomeRegulation of PKR and IRF-1 during hepatitis C virus RNA replication.Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differencesViral Determinants of Resistance to Treatment in Patients with Hepatitis CPretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to TherapyMutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment ResponsesThe Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon TherapyGenetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy responseMutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy andQuasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patientsViruses and the type I interferon antiviral system: induction and evasion.Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy.Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy.Apoptotic effects of a chimeric plant virus carrying a mimotope of the hepatitis C virus hypervariable region 1: role of caspases and endoplasmic reticulum-stress.Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination TherapyHCV genetic variability: from quasispecies evolution to genotype classification.Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment.Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.The role of HCV proteins on treatment outcomes.Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection.Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response.Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome
P2860
Q26801759-259F3F15-6F45-461F-A1B2-36F573E778D7Q27471683-E49AFA63-EB56-49C6-AECD-FF253DEDBBD2Q27472373-4EDD3616-455F-40C5-B0AD-4AA706E50333Q27477971-512730F7-F05F-40E1-B26F-84267E7EC528Q27478062-D2904A79-C2CF-4AA0-A546-4E280010688BQ27481007-C8AE0DB1-C16C-431D-9CCA-90D5C070D6D5Q27486410-270B4B61-2B54-487D-8043-728AA5BAAF06Q27489040-3E935DDD-1442-4235-830D-C91DD3F07A04Q27491275-7429E9E0-5F1F-425F-9FAC-B5D63DB4E0E9Q33866399-E3CF5183-1886-45CF-909E-7DA60BAC6B8CQ34099523-5E754218-5183-4CE4-A3C5-DDABECF2F30FQ34481770-AB9FC3CF-F54C-4FA4-9506-2B62593CF4A8Q35027514-CD9B555F-B99D-44FF-8DFD-46D676E254AEQ35547246-7C4EF9AF-A09A-47DF-8712-134D23652D77Q35977331-1F908565-9D0F-4442-BE5C-B86CC2518BC9Q36074656-4B44C29F-2944-44E0-BB08-42FAED609D1DQ36184075-266EB52E-1F41-4018-838C-0FB27F8537DBQ37425275-3B65F6FE-473A-4229-A84E-3ED017072212Q37772959-6ADE2114-6D1B-4119-B09E-756627EEA525Q38121422-625408B2-A4B8-4567-B602-46D1B2349759Q38224436-B0DEC072-3842-481B-8D16-46768E2D2ED3Q38668968-2B44C1FD-51CE-4949-9024-D2AD83745BA2Q39208854-AB69780E-10E6-460A-95C9-270A35E12CEBQ40218020-B7B61E9C-5F24-4FA0-8310-56E882D84E53Q41039294-5048219E-D24A-4362-AC05-ABB4F5BCB9BBQ42199023-1508615E-C424-409A-80AB-D3A9AE5A301BQ42977060-5D7A2E5C-1720-4802-A1EE-79AA7E6BD80BQ43037764-ED40A44B-03C8-4ABE-976D-179AD08E4BF7Q43039682-8181BF81-ACF7-4F06-936E-4D83BD01A4A0Q45347684-1A7F7DFA-807F-4088-9FA4-B8924B0D4B45Q58701375-34F2C938-F57C-4D87-A5D8-1E8F0729214E
P2860
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@en
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@nl
type
label
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@en
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@nl
prefLabel
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@en
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@nl
P2093
P356
P1433
P1476
Mutations in the E2-PePHD and ...... ing interferon alfa treatment.
@en
P2093
P304
P356
10.1053/JHEP.2000.20527
P407
P577
2000-12-01T00:00:00Z